Trials / Completed
CompletedNCT01912274
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Helsinn Healthcare SA · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and effectiveness of pracinostat when combined with azacitadine for patients who are 65 years of age or older and have Acute Myelogenous Leukemia (AML)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pracinostat | Elderly newly diagnosed patients will all receive pracinostat |
| DRUG | Azacitidine | Elderly newly diagnosed patients will all receive azacitadine |
Timeline
- Start date
- 2013-12-24
- Primary completion
- 2016-11-08
- Completion
- 2016-11-08
- First posted
- 2013-07-31
- Last updated
- 2021-02-09
- Results posted
- 2021-02-09
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01912274. Inclusion in this directory is not an endorsement.